Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Bronchodilators Market Grown from 2024 to 2025?

The size of the bronchodilators market has been experiencing robust growth in the past few years. This market will surge from $32.93 billion in 2024 to $35.66 billion in 2025, expanding at a compound annual growth rate (CAGR) of 8.3%. The past period of growth can be credited to an increasing elderly population, a higher number of asthma incidents, increased support from governmental bodies, an upturn in the ageing demographic, and escalating levels of air contamination worldwide.

What Growth Rate Is Anticipated for the Bronchodilators Market in the Coming Years?

The market for bronchodilators is projected to experience robust growth in the upcoming years, expanding to a value of $45.97 billion in 2029, with a compound annual growth rate (CAGR) of 6.6%. This predicted increase during the forecast period can be linked to the escalating incidence of COPD, heightened consciousness regarding the treatment of pulmonary diseases bolstered by intensified research and development initiatives, an uptick in pulmonary disorders, higher disposable income, and the rise in smoking rates. Key trends for the forecast period encompass advanced clinical studies and creative methodologies, expanding technological advancements, a high rate of pulmonary diseases such as COPD and asthma, the introduction of new products, and an increase in the patient count for acute respiratory infections.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13816&type=smp

Who Are the Leading Companies in the Bronchodilators Market?

Major companies operating in the bronchodilators market report are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Thermo Fisher Scientific, Abbott Laboratories, Sanofi S.A., GlaxoSmithKline plc, Siemens Healthcare GmbH, Merck & Co. Inc., AstraZeneca plc, Teva Pharmaceuticals Industries Ltd., Mylan N.V., Quest Diagnostics Incorporated., Boehringer Ingelheim International GmbH, Aurobindo Pharma Limited, Bio-Rad Laboratories Inc., Cipla Limited, Hikma Pharmaceutical plc, Amneal Pharmaceuticals LLC, Glenmark Pharmaceuticals Limited, Vectura Group Limited, Foundation Medicine Inc., Sun Pharmaceutical Industries Ltd., Amgen Inc., Kissei Pharmaceutical Co.Ltd., Mitsubishi Tanabe Pharma, Theron Pharmaceuticals, Viatris Inc.

What Are the Key Drivers of the Bronchodilators Market?

The escalating incidence of chronic obstructive pulmonary disease (COPD), a progressive condition characterized by long-term inflammation and restricted airflow in the lungs, is predicted to stimulate the expansion of the bronchodilator market. Bronchodilators, which help alleviate breathing difficulties by relaxing airway muscles and widening airways, are commonly employed in treating COPD. For example, a report issued by the Scottish Public Health Observatory, overseen by Public Health Scotland, a UK Population Health Centre, witnessed a surge in COPD rates as the effects of COVID-19 started to relent in March 2023. Specifically, the incidence in men rose from 83.2 to 97.6 cases per 100,000, while for women, the hike was from 72.6 to 97.3 cases per 100,000. Consequently, the rising incidence of chronic obstructive pulmonary disease (COPD) is fuelling the advancement of the bronchodilator market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13816&type=smp

What Are the Key Market Segments in the Bronchodilators Industry?

The bronchodilators market covered in this report is segmented –

1) By Type: Beta-Adrenergic Bronchodilators, Anticholinergic Bronchodilators, Xanthine Derivatives, Other Types

2) By Route of Administration: Oral, Nasal (Inhalation), Injectable

3) By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Reactions, Breathing Problem, Other Indications

4) By End-User: Hospitals, Specialty Clinics, Other End Users

Subsegments:

1) By Beta-Adrenergic Bronchodilators: Short-Acting Beta Agonists (SABAs), Long-Acting Beta Agonists (LABAs)

2) By Anticholinergic Bronchodilators: Short-Acting Anticholinergics, Long-Acting Anticholinergics

3) By Xanthine Derivatives: Theophylline, Aminophylline

4) By Other Types: Leukotriene Receptor Antagonists, Combination Therapies

What Are the Latest Trends in the Bronchodilators Market?

Leading businesses in the bronchodilator market are focusing on the development of innovative offerings, such as fixed-dose triple-drug blends for enhanced patient care. This new medication type consists of three active components in a single formulation, each component having a set dosage. Take for example, Lupin, a pharmaceutical company from India that released DIFIZMA, a fixed-dose triple-drug bronchodilator incorporating indacaterol, glycopyrronium, and mometasone to manage asthma, in January 2023. DIFIZMA, which is available as a dry powder inhalation, is noteworthy as the only fixed-dose combination that has received approval from the Drug Controller General of India (DCGI) to treat asthma that isn’t adequately controlled, by improving lung capacity, offering better symptom management, and minimizing exacerbations.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/bronchodilators-global-market-report

What Are the Key Regional Markets in the Bronchodilators Industry?

North America was the largest region in the bronchodilators market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bronchodilators market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13816

This Report Delivers Insight On:

1. How big is the bronchodilators market, and how is it changing globally?

2. Who are the major companies in the bronchodilators market, and how are they performing?

3. What are the key opportunities and risks in the bronchodilators market right now?

4. Which products or customer segments are growing the most in the bronchodilators market?

5. What factors are helping or slowing down the growth of the bronchodilators market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model